The GRIPHON study is indeed a groundbreaking step forward in pulmonary hypertension. ISHLT has a profound interest in these results as pulmonary hypertension is one of the key areas the society is concentrating on in the future.

LVADs continue to prove to be a viable treatment option for patients with heart failure. The ROADMAP trial is important to ISHLT as LVAD research and therapy continue to show positive results